| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| UNILIFE Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 53,62 | +0,28 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius Q3/2026 | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Quartalsergebnis
Fresenius Q3/2026 (News mit Zusatzmaterial)
04.11.2026 / 06:45 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,950 | +0,56 % | Fresenius Medical Care-Aktie: Seitwärts statt Aufbruch - lohnt sich der Einstieg?" | Die Fresenius Medical Care-Aktie befindet sich weiterhin in einem ausgeprägten Seitwärtstrend. Die Handelsspanne liegt derzeit zwischen 37 und 41 €. Am Mittwoch notiert das Papier bei 39,10 €. Der am... ► Artikel lesen | |
| UNITEDHEALTH | 361,80 | -0,33 % | UnitedHealth (UNH) BMO CDR (CAD Hedged): UnitedHealth (UNH) BMO CDR estimates distribution | ||
| GERRESHEIMER | 31,680 | +1,47 % | EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Gerresheimer AG
Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of... ► Artikel lesen | |
| THERMO FISHER | 643,00 | -0,12 % | Thermo Fisher Scientific (TMO) Is Benefiting From More Than Healthcare Demand: Here's the Overlooked AI Connection | ||
| STRATEC | 25,200 | +0,80 % | DEUTSCHE BANK RESEARCH stuft STRATEC BIOMEDICAL SYSTEMS AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Stratec nach einer Gewinnwarnung für 2026 auf "Hold" mit einem Kursziel von 21 Euro belassen. Mit einer Senkung der Jahresziele... ► Artikel lesen | |
| CERENOME | 0,508 | -12,41 % | Cerenome names Ron Andrews as chief business officer | ||
| BAXTER | 23,000 | -2,75 % | Baxter International Stock: Analyst Estimates & Ratings | ||
| ATOSSA THERAPEUTICS | 1,950 | +1,04 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax | Total revenue increased 28% for the quarter and 41% for the six months ended September 30, 2026 compared to same periods last yearU.S. revenue increased 93% for the quarter and 113% for the six months... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| CO-DIAGNOSTICS | 0,289 | 0,00 % | Co-Diagnostics Reports Third Quarter 2026 Financial Results | Two Regulatory Submissions Under Review in India and the U.S. Third Quarter Operating Expenses Down 12% Year Over YearPlatform Capabilities Expanding with ReadyGo Collaboration, India Connectivity and... ► Artikel lesen | |
| CYTOSORBENTS | 5,810 | 0,00 % | Cytosorbents Corp: CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement | PRINCETON, N.J., Sept. 23, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 14,550 | -0,07 % | LifeStance Health Prices Secondary Public Offering Of 45 Mln Shares At $13.12/Shr |